AVR logo

Anteris Technologies Global Corp. (AVR)

$5.32

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on AVR

Market cap

$518665042

EPS

-1.6

P/E ratio

--

Price to sales

294.29

Dividend yield

--

Beta

2.015292

Price on AVR

Previous close

$5.70

Today's open

$5.63

Day's range

$5.28 - $5.66

52 week range

$3.30 - $11.06

Profile about AVR

CEO

Wayne Paterson

Employees

174

Headquarters

Toowong,

Exchange

NASDAQ Global Market

Shares outstanding

97493429

Issue type

Common Stock

AVR industries and sectors

Healthcare

Medical Equipment & Supplies

News on AVR

Anteris Announces Late-Breaking PCR London Valves Data Release: One-Year DurAVR THV Outcomes in 100 Patients

MINNEAPOLIS and BRISBANE, Australia, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (Nasdaq: AVR; ASX: AVR) today announced that Rishi Puri, MD, PhD, Cleveland Clinic, will present one-year clinical and hemodynamic outcomes for the DurAVR® Transcatheter Heart Valve (THV) in a late-breaking session at PCR London Valves, held November 22–24, 2026, in London, United Kingdom. The presentation will report one-year clinical and hemodynamic outcomes from a pooled cohort of 100 patients with severe aortic stenosis who received the DurAVR THV.

news source

GlobeNewsWire • Nov 16, 2026

news preview

Anteris Technologies Announces Results for the Third Quarter of 2026

MINNEAPOLIS and BRISBANE, Australia, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR), a global healthcare company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today reported financial results for the quarter ended September 30, 2026, and provided a corporate update. Q3 2026 Highlights Continued execution of the PARADIGM Trial, with enrollment progressing across active sites in the U.S., Canada, Denmark, the Netherlands and France.

news source

GlobeNewsWire • Nov 10, 2026

news preview

Anteris Reports Medium-Size DurAVR THV Outcomes from the EMBARK Study at TCT 2026

MINNEAPOLIS and BRISBANE, Australia, Nov. 01, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global healthcare company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced 30-day clinical and hemodynamic outcomes for the Medium-size DurAVR® Transcatheter Heart Valve (THV) in twenty-two severe aortic stenosis patients with medium aortic annuli (aortic annulus area 492 ± 38 mm2). The DurAVR THV demonstrated single digit mean gradients, large effective orifice areas (EOAs), no moderate or severe paravalvular leaks and no valve related mortality, with 100% freedom from moderate or severe prosthesis-patient mismatch* (PPM) in a cohort of medium annuli patients from the EMBARK Study.

news source

GlobeNewsWire • Nov 1, 2026

news preview

Anteris Announces Upcoming Data Release for Medium-Size DurAVR THV from EMBARK Study at TCT 2026

MINNEAPOLIS and BRISBANE, Australia, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) today announced that Azeem Latib, MD, will present the first 30-day clinical and hemodynamic outcomes for its medium-size DurAVR® Transcatheter Heart Valve (THV) at TCT® 2026 – The 38th Annual Transcatheter Cardiovascular Therapeutics Conference, taking place in San Diego, California, October 31-November 3, 2026. The presentation will report 30-day outcomes in patients with severe aortic stenosis who received the medium-size DurAVR THV in the ongoing EMBARK study.

news source

GlobeNewsWire • Oct 27, 2026

news preview

Anteris Technologies secures German clearance to expand PARADIGM heart valve trial

Anteris Technologies Pty Ltd (ASX:AVR, NASDAQ:AVR) has secured full German regulatory clearance for its pivotal PARADIGM trial, allowing the company to begin recruiting patients in Europe's largest transcatheter aortic valve replacement market. Germany's Federal Institute for Drugs and Medical Devices has cleared the DurAVR® Transcatheter Heart Valve study for patients with severe calcific aortic stenosis, opening the way for Anteris to activate leading German clinical centres and broaden the trial's European footprint.

news source

Proactive Investors • Oct 20, 2026

news preview

Anteris Advances Global PARADIGM Trial Expansion with German Regulatory Clearance

MINNEAPOLIS and BRISBANE, Australia, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) announced today that it has received full regulatory clearance from the German Federal Institute for Drugs and Medical Devices (BfArM) for the DurAVR® Transcatheter Heart Valve (THV) global pivotal trial for patients with severe calcific aortic stenosis (the “PARADIGM Trial”). This clearance enables Anteris to initiate patient recruitment at leading German centers and represents an important step in expanding the PARADIGM Trial's European footprint.

news source

GlobeNewsWire • Oct 20, 2026

news preview

Anteris to Present at September Healthcare Investor Conferences

MINNEAPOLIS and BRISBANE, Australia, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global healthcare company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, is pleased to advise that Vice Chairman and Chief Executive Officer, Wayne Paterson, will be presenting at the Cantor Global Healthcare Conference, the Wells Fargo 21st Annual Healthcare Conference and the Morgan Stanley 24th Annual Global Healthcare Conference. The details of each conference are as follows: Cantor Global Healthcare Conference Date: Wednesday, September 9, 2026 (US time) Format: Fireside chat with analyst, Gabie Ingoglia, and 1x1 meetings Time: 11:30AM (US EST) Room: Track 1 – Metropolitan Room Location: Waldorf Astoria Hotel, New York Wells Fargo Healthcare Conference Date: Thursday, September 10, 2026 (US time) Format: Fireside chat with analyst, Larry Biegelsen, and 1x1 meetings Time: 9:30AM (US EST) Room: Track 1 – Picasso 6 Location: Encore Boston Harbor Hotel, Boston Morgan Stanley Healthcare Conference Date: Monday, September 14, 2026 (US time) Format: Fireside chat with Morgan Stanley Healthcare Team Time: 9:15AM (US EST) Room: Soho Complex 7th Floor Location: Sheraton Times Square Hotel, New York About Anteris Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global healthcare company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function.

news source

GlobeNewsWire • Aug 31, 2026

news preview

Anteris Technologies Announces Results for the Second Quarter of 2026

MINNEAPOLIS and BRISBANE, Australia, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global healthcare company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today reported financial results for the quarter ended June 30, 2026, and provided a corporate update. Q2 2026 Highlights Secured U.S. Medicare reimbursement eligibility for the global pivotal PARADIGM Trial under a Centers for Medicare & Medicaid Services (CMS) national coverage policy, enabling reimbursement for eligible procedures at U.S. sites.

news source

GlobeNewsWire • Aug 11, 2026

news preview

Anteris Advances Global PARADIGM Expansion with French Regulatory Clearance

MINNEAPOLIS and BRISBANE, Australia, June 08, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) announced today that it has received full regulatory clearance from the French National Agency for Medicines and Health Products Safety (ANSM) for the DurAVR® Transcatheter Heart Valve (THV) global pivotal trial in patients with severe calcific aortic stenosis (the “PARADIGM Trial”). This authorization marks a significant milestone in the Company's clinical and regulatory strategy and enables patient recruitment to commence at leading centers in France.

news source

GlobeNewsWire • Jun 8, 2026

news preview

Anteris Appoints Susan Knight and Stephen Denaro to its Board of Directors

MINNEAPOLIS and BRISBANE, Australia, May 13, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, announced the appointment of Ms. Susan Knight and Mr.

news source

GlobeNewsWire • May 13, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Anteris Technologies Global Corp.

Open an M1 investment account to buy and sell Anteris Technologies Global Corp. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in AVR on M1